190 related articles for article (PubMed ID: 3883502)
1. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
Geller J
Semin Oncol; 1985 Mar; 12(1 Suppl 1):28-35. PubMed ID: 3883502
[TBL] [Abstract][Full Text] [Related]
2. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
3. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
[TBL] [Abstract][Full Text] [Related]
4. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
5. Newer methods of hormonal therapy for prostate cancer.
Soloway MS
Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
[TBL] [Abstract][Full Text] [Related]
6. Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
Geller J
J Androl; 1991; 12(6):364-71. PubMed ID: 1769904
[TBL] [Abstract][Full Text] [Related]
7. Advantages of total androgen blockade in the treatment of advanced prostate cancer.
Geller J; Albert J; Vik A
Semin Oncol; 1988 Apr; 15(2 Suppl 1):53-61. PubMed ID: 3285484
[TBL] [Abstract][Full Text] [Related]
8. Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma.
Geller J
Urol Clin North Am; 1991 Feb; 18(1):83-91. PubMed ID: 1825145
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
10. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
11. Adrenal androgen blockade in relapsed prostate cancer.
Geller J; Albert JD
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1127-31. PubMed ID: 2934257
[TBL] [Abstract][Full Text] [Related]
12. Changes in the androgen levels in the ventral prostate of spontaneously hypertensive rats after castration.
Hu M; Xin D; Chen J; Sun G; Wang Y; Na Y
BJU Int; 2009 Aug; 104(3):406-11. PubMed ID: 19239443
[TBL] [Abstract][Full Text] [Related]
13. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
15. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the management of advanced prostate cancer.
Tyrrell CJ
Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
[TBL] [Abstract][Full Text] [Related]
18. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
Sandow J; von Rechenberg W; Engelbart K
Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602
[TBL] [Abstract][Full Text] [Related]
20. Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue.
Liu J; Geller J; Albert J; Kirshner M
J Clin Endocrinol Metab; 1985 Jul; 61(1):129-33. PubMed ID: 2581988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
